Storys zum Thema Swiss

Folgen
Keine Story zum Thema Swiss mehr verpassen.
Filtern
  • 10.10.2008 – 11:00

    MARMARA MINING PLC

    Roadshow MARMARA MINING PLC

    London (ots) - EQUITY Capital increase of approximately 6.315.850 GBP, to finance further growth in TURKEY From 16st October until 4th November, at the earliest, MARMARA MING PLC will present the company to investors during an international roadshow and encourage the public to purchase shares in MARMARA MINING PLC. The subscription period, during which investors can submit applications for shares, is expected to commence on 12th September 2008, by which time the price ...

  • 23.09.2008 – 07:00

    Kardex Systems AG

    Kardex Remstar International Group: Change in the Management Board of Kardex AG

    Zurich (ots) - The Chief Financial Officer of Kardex AG, Reto Welte, will be leaving the Group at the end of March 2009 to take on a new challenge. The Board of Directors and Management Board regret his decision and would like to thank him for his services and wish him all the best for the future. Calendar of events 10 March 2009Annual Media Conference ...

  • 19.09.2008 – 14:37

    Emmentaler Switzerland Tradition

    New organisation "Emmentaler Switzerland Tradition"

    Langnau. Switzerland (ots) - The World Champion cheese makers from Switzerland, Christian Wüthrich from Rüderswil, Anton Wyss from Mutten and Walo von Mühlenen have decided along with the dairies, Leimiswil, Schärlig, Stettenbach Wohlen and Schüpbach, to create a new organisation for Emmental produced in the traditional way, with only one production per day, and produced with the milk from the same village. The ...

  • 12.09.2008 – 17:00

    Helsinn Healthcare SA

    Helsinn Healthcare SA: Palonosetron - The long-lasting antiemetic action finds its basis

    New data on the mechanism of action of the second generation 5-HT3 antagonist palonosetron presented today at the 33rd ESMO Congress in Stockholm, Sweden Stockholm, Sweden (ots) - New data presented today at the 33rd ESMO (European Society of Medical Oncology) Congress in Stockholm may contribute to explain the reason why palonosetron, a second generation 5-HT3 ...